Skip to content
Parakho

Sanofi India Ltd

NSE SANOFIBSE 500674

Q1 FY27, unaudited

Revenue
₹437.70 Cr
Profit after tax
₹83.50 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year ago6M FY27
Revenue from operations437.70+7.73%910.00
Other income6.20−28.74%10.60
Total income443.90+6.96%920.60
Employee benefit expense44.60−0.67%87.40
Finance costs0.30−25.00%0.60
Depreciation & amortisation8.90−2.20%17.90
Total expenses331.60+3.33%670.40
Profit before tax112.30+19.34%250.20
Tax expense28.80+17.07%64.10
Profit after tax83.50+20.14%186.10
Total comprehensive income83.50+20.14%186.10
Earnings per share
Earnings per share, basic₹36.26₹80.81
Earnings per share, diluted₹36.26₹80.81

Q1 FY27 and 6M FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

Earnings call

Q1 FY27

Sanofi India reported quarter two 2026 results with diabetes business growth of close to 14%, driven by Toujeo and Soliqua, while the partnership business with Emcure and Cipla grew 2% in the quarter. Profit before tax and exceptional items rose 19% year-on-year to INR 112 crores from INR 94 crores, with margin improving to 27% of net sales from 24%. Management discussed export market challenges in Australia offset partly by other markets, and noted cash balance grew 34%.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Filings

12 shown · 44 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 13 Aug 2026.